Twi Pharms Company Profile
What is the competitive landscape for TWI PHARMS
TWI PHARMS has thirty-one approved drugs.
There is one US patent protecting TWI PHARMS drugs. There is one tentative approval on TWI PHARMS drugs.
Summary for Twi Pharms
| US Patents: | 1 |
| Tradenames: | 29 |
| Ingredients: | 26 |
| NDAs: | 31 |
Drugs and US Patents for Twi Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Twi Pharms | GUANFACINE HYDROCHLORIDE | guanfacine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201408-002 | Jun 2, 2015 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Twi Pharms | FLUPHENAZINE HYDROCHLORIDE | fluphenazine hydrochloride | TABLET;ORAL | 215848-003 | Apr 1, 2022 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Twi Pharms | KLOR-CON | potassium chloride | TABLET, EXTENDED RELEASE;ORAL | 218979-001 | Oct 28, 2024 | AB2 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Twi Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Twi Pharms | TENORETIC 50 | atenolol; chlorthalidone | TABLET;ORAL | 018760-002 | Jun 8, 1984 | 3,663,607 | ⤷ Start Trial |
| Twi Pharms | NAPRELAN | naproxen sodium | TABLET, EXTENDED RELEASE;ORAL | 020353-001 | Jan 5, 1996 | 5,637,320 | ⤷ Start Trial |
| Twi Pharms | TENORETIC 100 | atenolol; chlorthalidone | TABLET;ORAL | 018760-001 | Jun 8, 1984 | 3,663,607 | ⤷ Start Trial |
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-002 | Approved Prior to Jan 1, 1982 | 3,836,671 | ⤷ Start Trial |
| Twi Pharms | TENORMIN | atenolol | TABLET;ORAL | 018240-004 | Apr 9, 1990 | 3,836,671 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TWI PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 450 mg | ➤ Subscribe | 2013-02-28 |
International Patents for Twi Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008038155 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Twi Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2316456 | 300918 | Netherlands | ⤷ Start Trial | PRODUCT NAME: NALTREXON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER NALTREXONHYDROCHLORIDE, EN BUPROPION OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER BUPROPIONHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
| 1506211 | 92496 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: COMBINAISON DE DAPAGLIFLOZINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DE METFORMINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,TELLE QUE PROTEGEE PAR LE BREVET DE BASE EP1506211 B1 |
| 1131065 | 1490039-3 | Sweden | ⤷ Start Trial | PRODUCT NAME: DIMETHYL FUMARATE; REG. NO/DATE: EU/1/13/837 20140130 |
| 2498758 | LUC00152 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: METFORMINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; SAXAGLIPTINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; DAPAGLIFLOZINE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1401 20191113 |
| 0656775 | CR 2000 00018 | Denmark | ⤷ Start Trial | PRODUCT NAME: BUPROPIONHYDROCHLORID; NAT. REG. NO/DATE: 31347 20000606; FIRST REG. NO/DATE: NL 24160 19991201 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
